<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448835</url>
  </required_header>
  <id_info>
    <org_study_id>N17PND</org_study_id>
    <nct_id>NCT03448835</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)</brief_title>
  <acronym>PANDA</acronym>
  <official_title>Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Non-metastatic, Resectable Gastric and GE-junction Cancer: The PANDA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this explorative study, patients with resectabel cancer of the stomach or
      stomach-oesophagealjunction cancer will receive neoadjuvant treatment.

      The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and
      capecitabine, oxaliplatin and docetaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single-centre, open-label, monocenter study, the investigators will enroll 20
      patients with resectable cancer of the stomach of GEJunction.

      All patients will be treated with 1 cycle of atezolizumab monotherapy, followed by 4 cycles
      of combinationtherapy of atezolizumab, capecitabine, oxaliplatin and docetaxel, followed by
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 7, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single group, open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events following treatment (safety)</measure>
    <time_frame>until 100 days after last patient last study drug treatment</time_frame>
    <description>Adverse events will be assessed (according to CTC-AE v4.0) during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathological tumor regression grade</measure>
    <time_frame>Within 6 months after last patient inclusion</time_frame>
    <description>determined using the Mandard tumor regression grading system</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stomach Cancer</condition>
  <condition>Gastro Esophageal Junction Cancer</condition>
  <arm_group>
    <arm_group_label>atezolizumab and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>atezolizumab 1200 mg 5 cycles</description>
    <arm_group_label>atezolizumab and chemotherapy</arm_group_label>
    <other_name>MPDL3280A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>capecitabine 850 mg /m2 4 cycles</description>
    <arm_group_label>atezolizumab and chemotherapy</arm_group_label>
    <other_name>L01BC06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin 100 mg/m2 4 cycles</description>
    <arm_group_label>atezolizumab and chemotherapy</arm_group_label>
    <other_name>L01XA03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>docetaxel 50 mg/m2 4 cycles</description>
    <arm_group_label>atezolizumab and chemotherapy</arm_group_label>
    <other_name>L01CD02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  patients age 18 and older

          -  primary resectable, histologically confirmed gastric or GEJ adenocarcinoma

        Exclusion Criteria:

          -  no signs of distant metastases

          -  no active or history of autoimmune disease or immune deficiency

          -  no significant cardiovascular disease

          -  no major surgical procedure within 4 weeks prior to initiation of study treatment

          -  no current treatment with anti-viral therapy or HBV

          -  no pregnancy or breastfeeding

          -  no history of malignancy within 3 years prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myriam Chalabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elvira Nuijten, MSc</last_name>
    <phone>+3120512</phone>
    <phone_ext>2671</phone_ext>
    <email>e.nuijten@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Nuijten, MSc</last_name>
      <phone>+3120512</phone>
      <phone_ext>2671</phone_ext>
      <email>e.nuijten@nki.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>short term immunotherapy</keyword>
  <keyword>surgical resection</keyword>
  <keyword>atezolizumab</keyword>
  <keyword>capecitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

